PMID- 15026619
OWN - NLM
STAT- MEDLINE
DCOM- 20040629
LR  - 20220330
IS  - 0167-6806 (Print)
IS  - 0167-6806 (Linking)
VI  - 84
IP  - 3
DP  - 2004 Apr
TI  - Her-2/neu gene amplification and protein expression in primary male breast 
      cancer.
PG  - 215-23
AB  - The role of HER-2/ neu in male breast cancer is not well defined. The purpose of 
      the current study was to measure the frequency of HER-2/ neu expression in 
      primary male breast cancer, to demonstrate HER-2/ neu gene amplification in cases 
      found to be positive for protein overexpression, and to correlate HER-2/ neu 
      positivity with clinicopathological variables. Formalin-fixed, paraffin-embedded 
      archival material from 99 primary male breast carcinomas was evaluated by 
      immunohistochemistry (IHC) using the HercepTest (DAKO Corp., Hamburg, Germany). 
      Scoring was performed according to established guidelines. All cases 
      demonstrating HER-2/ neu staining by IHC (1+/2+ and 3+) were analyzed for HER-2/ 
      neu gene amplification by fluorescence in situ hybridization (FISH) utilizing the 
      PathVysion assay (Vysis Corp., Downers Grove, Illinois) to assess HER-2/ neu 
      amplification status. The immunohistochemical staining of the HER-2/ neu protein 
      revealed HER-2/ neu positivity in 15/99 (15.1%) cases, eight tumors showed 2+ and 
      7 tumors 3+ staining. HER-2/ neu gene amplification was observed in 11/99 cases 
      (11,1%), and all of the 3+ and 4/8 from the 2+ cases were amplified. HER-2/ neu 
      gene amplification/protein overexpression did not correlate with tumor state, 
      histological grade or estrogen/progesterone receptor status nor the axillary 
      lymph node status. This is the first comprehensive study of HER-2/ neu gene 
      amplification by FISH analysis in primary male breast cancer. Compared to female 
      primary breast cancer the percentage of HER-2/ neu positivity in our study was 
      lower. Our data provide first evidence for HER-2/ neu gene amplification in male 
      breast cancer. Further studies should be addressed on the potential application 
      of the monoclonal rhuMAB HER-2/ neu antibody for treatment of HER-2/ neu positive 
      male breast cancer.
FAU - Rudlowski, Christian
AU  - Rudlowski C
AD  - Department of Gynecology and Obstetrics, University Hospital Heidelberg, 
      Heidelberg, Germany. rudlowski@t-online.de
FAU - Friedrichs, Nicolaus
AU  - Friedrichs N
FAU - Faridi, Andree
AU  - Faridi A
FAU - Fuzesi, Lazlo
AU  - Fuzesi L
FAU - Moll, Roland
AU  - Moll R
FAU - Bastert, Gunther
AU  - Bastert G
FAU - Rath, Werner
AU  - Rath W
FAU - Buttner, Reinhard
AU  - Buttner R
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Breast Neoplasms, Male/*genetics/pathology
MH  - *Gene Amplification
MH  - *Gene Expression Profiling
MH  - *Gene Expression Regulation, Neoplastic
MH  - Genes, erbB-2/*genetics
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Receptor, ErbB-2/*biosynthesis
MH  - Retrospective Studies
EDAT- 2004/03/18 05:00
MHDA- 2004/06/30 05:00
CRDT- 2004/03/18 05:00
PHST- 2004/03/18 05:00 [pubmed]
PHST- 2004/06/30 05:00 [medline]
PHST- 2004/03/18 05:00 [entrez]
AID - 5255954 [pii]
AID - 10.1023/B:BREA.0000019953.92921.7e [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2004 Apr;84(3):215-23. doi: 
      10.1023/B:BREA.0000019953.92921.7e.